Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01508676
Other study ID # 2011p000897
Secondary ID
Status Active, not recruiting
Phase N/A
First received January 4, 2012
Last updated February 24, 2015
Start date November 2011
Est. completion date December 2015

Study information

Verified date February 2015
Source Massachusetts General Hospital
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review BoardUnited States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2 weeks.

The U.S. Food and Drug Administration (FDA) has approved Pennsaid to treat osteoarthritis (bone pain), but the FDA has not approved Pennsaid to treat neuropathic (nerve) pain.

The research study will compare Pennsaid to placebo.


Description:

The research study will compare Pennsaid to placebo. The placebo looks like Pennsaid, but it doesn't contain any Pennsaid. The investigators use placebos in research to see if the results are due to the study drug or to other reasons. At some time during the study the investigators will give the patient Pennsaid. At another time, the investigators will give the patient placebo. The investigators are using Quantitative Sensory Testing (QST), which is temperature testing before and after using the study drug to see if Pennsaid is helpful in reducing people's nerve pain.

In this test, a small metal plate, about the size of a matchbox, is put on the area where the patient has pain. The plate is connected to a computer that can warm or cool the plate. The patient will use a computer mouse button to tell us when the plate feels warm. The QST machine is approved by the Food and Drug Administration (FDA). It is often used by nerve doctors to see if a person has neuropathy (pain caused by damage to a nerve).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 48
Est. completion date December 2015
Est. primary completion date February 2015
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Subject will be between 18 and 80 years of age.

2. Subject has not been on Pennsaid or other topical non-steroid anti-inflammatory drugs for at least one month.

3. Subject agrees to make no change in his/her current pain medications during the entire study period. This requirement will ensure that valid comparisons of primary and secondary measures can be made before and after the study.

4. Subject has a VAS pain score of 4 or above at the beginning of the study.

5. Subject has had a neuropathic pain condition such as those listed above for at least three months. This requirement is to avoid clinical uncertainty from an unstable pain condition and to minimize the study variation.

6. Female subjects of childbearing age must have a negative urine pregnancy test at the initial visit.

Exclusion Criteria:

1. Subject has documented severe liver or renal disease that will affect the elimination of Pennsaid or is subject to the adverse effect of Pennsaid on these organs. (Renal dysfunction is defined as eGFR < 60. Hepatic dysfunction is defined as LFTs = 3X ULN.)

2. Subject has pending litigation related to the neuropathic pain condition.

3. Subject has active skin lesion or open wound at the site of Pennsaid application (e.g., active shingles with skin lesions).

4. Subject is pregnant or lactating.

5. Subject has scar tissue or sensory deficit at the site of QST.

6. Subject is allergic to diclofenac or has cross-sensitivity to other non-steroid anti-inflammatory drugs.

7. Subject has a positive urine (illicit) drug test.

8. Subjects who experience asthma, urticaria or an allergic type reaction when taking aspirin or NSAIDs.

9. Subjects undergoing coronary artery bypass surgery.

10. Subject with a known history of cardiovascular disease, ulcer, gastrointestinal bleed or impaired renal function.

11. Subjects currently using NSAIDS.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Intervention

Drug:
Pennsaid

Placebo (2.3% DMSO solution)


Locations

Country Name City State
United States MGH Center for Translational Pain Research Boston Massachusetts

Sponsors (1)

Lead Sponsor Collaborator
Massachusetts General Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Effect of Pennsaid on Clinical Neuropathic Pain Four times throughout the study the subject will fill out questionnaires, SF-36s, and take QSTs. Five weeks. Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04066933 - Forms of Cervical Brachial Syndrome Treated With Plasma Concentrate Enriched for A2M
Completed NCT01202227 - An Open-Label Long-Term Study Of Pregabalin For The Treatment Of Central Neuropathic Pain Phase 3
Completed NCT00922987 - Clinical Study With Lyrica In Patients Suffering From Epilepsy
Terminated NCT00964990 - A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42160443 in Patients With Neuropathic Pain (Postherpetic Neuralgia and Post-traumatic Neuralgia) Phase 2
Recruiting NCT00740571 - Amitriptyline or Pregabalin to Treat Neuropathic Pain in Incurable Cancer Phase 3
Terminated NCT02747758 - Transcranial Direct Current Stimulation (tDCS) in Chronic Neuropathy N/A
Completed NCT05464199 - Home-based EEG Neurofeedback for Chronic Neuropathic Pain Phase 1
Completed NCT02490436 - Novel Treatment Option for Neuropathic Pain Phase 2
Completed NCT01974791 - GET Living: Graded Exposure Treatment for Children and Adolescents With Chronic Pain N/A
Completed NCT01279018 - Persistent Pain After Breast Cancer Treatment With Docetaxel N/A
Not yet recruiting NCT00944502 - To Evaluate the Efficacy and Tolerability of the Use of Vitatonus Dexa Compared to Dexamethasone in Patients With Neuralgia of Various Origins Phase 3
Completed NCT02957851 - EMONO for the Treatment of Peripheral Neuropathic Pain Phase 2
Completed NCT02180880 - Symptom Based Treatment of Neuropathic Pain Phase 4
Completed NCT00631943 - A Study to Evaluate the Efficacy and Safety of Pregabalin (Lyrica) for the Treatment of Nerve Pain Phase 3
Completed NCT03973983 - Comparison of Ultrasound-guided Transgluteal and Finger-guided Transvaginal Pudendal Nerve Block Techniques N/A
Terminated NCT03296111 - Patients With Ocular Neuropathic Pain: Description of Pain and Impact on Their Quality of Life
Not yet recruiting NCT06398847 - Virtual Reality (VR) Self-Hypnosis Software N/A
Terminated NCT02460107 - Botulinum Toxin Type A for Neuropathic Pain in Patients With Diabetic Peripheral Polyneuropathy Early Phase 1
Recruiting NCT01788410 - MRI-Guided Cryoablation to Alleviate Pain in Head, Neck and Spine
Completed NCT01855594 - Study to Evaluate the Efficacy of Lithium Carbonate in Spinal Cord Injury Patients With Neuropathic Pain Phase 2